Emergency caesarean simulator to help junior doctors
For the first time, junior doctors will be given the chance to practice an emergency caesarian procedure using a life-size simulator called Desperate Debra.
An emergency caesarian is often called for following the baby’s head becoming stuck in the mother’s pelvis. From this difficult position, the head is required to be pushed back into the uterus before an incision is made in the abdomen to retrieve the baby.
This highly complex and intricate procedure is often an unwelcome shock to doctors who are thrust into the situation for the first time in a real-life scenario. While the training should prepare the doctors for such an eventuality, the advantages that a real-life simulation would give trainees could be invaluable.
To read the latest edition of Healthcare Global, click here
- Celebrity fad or medical marvel
- Autism diagnoses could be possible
- Scientists invent smoking vaccination
British medical team and manufacturers, Adam,Rouilly developed Debra, realising the need for the training manikin, given that 10-20 emergency caesarians are carried out every day.
“Of all the women who reach full dilatation, somewhere between about two and five percent will end up needing this type of operation,” explained Andy Shennan, professor of obstetrics at Guy’s and St Thomas’s Hospital.
Shennan was also a pivotal figure in developing the projects and further expressed the significance of Debra:
“Because caesareans are any time day or night, it is very likely that the doctor who’s doing this is not that experienced and may not have come across a similar delivery before. So the first time you’re exposed to this problem is often in a real-life situation.
“There are other teaching models a bit like it, but certainly nothing that mimics the difficulty of getting the head out during a caesarean.”
The device, designed by Dr Graham Tydeman of NHS Fife, has received so much critical acclaim upon its unveiling that it is now thought that it will be used to further refine the procedure, as well as using it as a benchmark for future birth simulators.
“The model is really attractive in the sense that you don’t have lots of calibration and electronics and keyboards and things to go wrong, which has been an issue with other models,” asserted Gabriel Ogwo, product development manager at Adam,Rouilly.
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.